Fidelis Capital Partners LLC Has $4.31 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV)

Fidelis Capital Partners LLC grew its position in shares of AbbVie Inc. (NYSE:ABBV) by 11.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,967 shares of the company’s stock after acquiring an additional 2,347 shares during the quarter. Fidelis Capital Partners LLC’s holdings in AbbVie were worth $4,307,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Mount Yale Investment Advisors LLC increased its position in shares of AbbVie by 20.1% in the second quarter. Mount Yale Investment Advisors LLC now owns 28,223 shares of the company’s stock valued at $4,841,000 after acquiring an additional 4,727 shares during the last quarter. Frank Rimerman Advisors LLC boosted its position in AbbVie by 72,275.0% during the second quarter. Frank Rimerman Advisors LLC now owns 26,055 shares of the company’s stock valued at $4,469,000 after purchasing an additional 26,019 shares during the last quarter. ProShare Advisors LLC grew its stake in AbbVie by 2.0% in the second quarter. ProShare Advisors LLC now owns 1,309,684 shares of the company’s stock valued at $224,637,000 after purchasing an additional 26,088 shares in the last quarter. Profund Advisors LLC increased its position in shares of AbbVie by 32.8% during the 2nd quarter. Profund Advisors LLC now owns 47,004 shares of the company’s stock worth $8,062,000 after purchasing an additional 11,603 shares during the last quarter. Finally, Kowal Investment Group LLC raised its stake in shares of AbbVie by 4.7% during the 2nd quarter. Kowal Investment Group LLC now owns 15,006 shares of the company’s stock worth $2,574,000 after purchasing an additional 671 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Buying and Selling at AbbVie

In related news, Chairman Richard A. Gonzalez sold 66,500 shares of the firm’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $186.52, for a total value of $12,403,580.00. Following the transaction, the chairman now owns 446,599 shares in the company, valued at $83,299,645.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other AbbVie news, Chairman Richard A. Gonzalez sold 282,845 shares of the company’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $175.00, for a total transaction of $49,497,875.00. Following the completion of the sale, the chairman now directly owns 513,099 shares in the company, valued at $89,792,325. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Richard A. Gonzalez sold 66,500 shares of AbbVie stock in a transaction on Monday, August 5th. The shares were sold at an average price of $186.52, for a total value of $12,403,580.00. Following the completion of the transaction, the chairman now owns 446,599 shares in the company, valued at approximately $83,299,645.48. The disclosure for this sale can be found here. Insiders own 0.25% of the company’s stock.

AbbVie Stock Down 0.1 %

ABBV opened at $193.47 on Friday. The company has a debt-to-equity ratio of 8.51, a quick ratio of 0.71 and a current ratio of 0.81. The stock has a fifty day moving average of $189.35 and a 200-day moving average of $175.80. AbbVie Inc. has a fifty-two week low of $135.85 and a fifty-two week high of $199.95. The company has a market capitalization of $341.64 billion, a P/E ratio of 57.41, a P/E/G ratio of 2.66 and a beta of 0.64.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Thursday, July 25th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.08. AbbVie had a net margin of 9.71% and a return on equity of 203.66%. The firm had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.02 billion. During the same quarter in the previous year, the firm posted $2.91 EPS. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. On average, equities analysts expect that AbbVie Inc. will post 10.86 EPS for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th will be issued a $1.55 dividend. The ex-dividend date of this dividend is Tuesday, October 15th. This represents a $6.20 annualized dividend and a yield of 3.20%. AbbVie’s dividend payout ratio is presently 183.98%.

Analysts Set New Price Targets

ABBV has been the subject of several analyst reports. Piper Sandler Companies reissued an “overweight” rating and issued a $190.00 target price on shares of AbbVie in a research note on Wednesday, July 3rd. Cantor Fitzgerald restated an “overweight” rating and set a $200.00 price objective on shares of AbbVie in a research note on Monday, August 5th. William Blair raised shares of AbbVie to a “strong-buy” rating in a report on Friday, August 30th. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a report on Wednesday, June 5th. Finally, Wells Fargo & Company upped their price objective on AbbVie from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Friday, July 26th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $191.64.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.